Substituted alkylamines and methods of use

Abstract

This Amgen patent application provides a series of 2-aminoheterocyclic amides described as useful for the treatment of cancer and angiogenesis-related disorders. These compounds appear to be related to a nicotinamide series previously described by Novartis as vascular endothelial growth factor (VEGF) inhibitors. The compounds differ from the Novartis series in that they rely preferentially on an aminobicycloaromatic group at the 2-position of the nicotinamide. Based on the data provided in the application, a 6-amino-(1H) indazole appears to be a particularly important sidechain for these compounds, providing consistent cell activity despite a range of substituted amides at the 3-position of the nicotinamide.

• ngiogenesis inhibitor
• indazole
• nicotinamide
• PTK-787
• tyrosine kinase inhibitor (TKI)
• vascular endothelial growth factor (VEGF) inhibitor